Medpace
Medpace is a publicly traded, full-service Contract Research Organization (CRO) providing end-to-end clinical development services — anchored by its proprietary ClinTrak platform and wholly-owned central labs — primarily to small-to-mid-sized biotech and biopharma sponsors globally.
- Company typePublic
- Founded1992
- HeadquartersCincinnati, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Medpace does
Medpace, Inc. is a publicly traded (NASDAQ: MEDP), full-service Contract Research Organization (CRO) founded in 1992 by August Troendle, MD, and headquartered in Cincinnati, Ohio. The company provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV studies, with documented therapeutic depth in oncology, cardiovascular, metabolic, neuroscience, rare diseases, cell and gene therapy, and several specialty areas. Medpace's service model is anchored by a proprietary integrated technology platform — ClinTrak — which unifies clinical trial management, EDC, IRT, ECG, imaging, and lab information management, and is supplemented by patient-facing tools (TrialPACE, OnPACE), feasibility/analytics modules (IntelliPACE, ClinTrak Data Explorer), and recruitment methodology (ExcelliPACE).
Underpinning the technology platform are wholly-owned central laboratories in Cincinnati, Belgium, Shanghai, and Singapore; a Bioanalytical Lab; Imaging Core Lab and Cardiovascular/ECG Core Lab; a Phase I clinical pharmacology unit; and wearable biosensor capabilities. Medpace operates across 46 countries with regional subsidiaries spanning North America, EMEA, Asia-Pacific, and Latin America, supported by a workforce of approximately 5,200–6,200 employees.
Commercially, Medpace targets primarily small-to-mid-sized biotech and biopharma sponsors, distributing services exclusively through direct, consultative enterprise sales under fixed-price, milestone-based multi-year contracts. Revenue is recognized over time as services are rendered. FY2025 revenue was $2.53 billion with net income of $451.1 million; Q1 2026 revenue grew 26.5% year-over-year to $706.6 million, with FY2026 guidance of $2.755–$2.855 billion. The company has grown exclusively through organic expansion over more than 30 years, avoiding the M&A activity common among peers.
Medpace firmographics
Firmographics- Name
- Medpace
- Legal name
- Medpace, Inc.
- Website
- https://medpace.com
- Company type
- Public
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Medpace is a publicly traded, full-service Contract Research Organization (CRO) providing end-to-end clinical development services — anchored by its proprietary ClinTrak platform and wholly-owned central labs — primarily to small-to-mid-sized biotech and biopharma sponsors globally.
- Ownership category
- akta.pro rank
Medpace industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
Keywords
Where Medpace is headquartered
LocationHeadquarters
- HQ city
- Cincinnati
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Medpace business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Medpace generates the vast majority of its revenue through fixed-price, project-based contracts for clinical research services spanning preclinical through Phase IV. Revenue is recognized over time as services are rendered, with contracts typically structured as standalone performance obligations tied to specific milestones or deliverable phases. Upsell and expansion occur as sponsors advance drugs through additional trial phases or add therapeutic area programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based contracts negotiated per sponsor engagement |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Medpace product offering
Product offeringCore offering
Medpace is a global full-service Contract Research Organization (CRO) that provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV. Its offerings are anchored by the proprietary ClinTrak technology platform and supported by wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, Cardiovascular & ECG Core Lab, and a Phase I Unit, delivering study start-up, clinical trial management, monitoring, regulatory affairs, biostatistics, pharmacovigilance, medical writing, and quality assurance through a single-vendor outsourcing model.
Product overview
Medpace is a global full-service Contract Research Organization (CRO) providing end-to-end drug and medical device development services, primarily serving small and mid-sized biopharma companies. The company's core offering is anchored by its proprietary ClinTrak technology platform, an integrated Clinical Trial Management System that unifies study management, EDC, IRT, ECG, imaging, and lab modules, supplemented by patient-facing tools (TrialPACE, OnPACE) and analytics (ClinTrak Data Explorer). Supporting the platform are wholly-owned, integrated service units: Central Laboratories, Bioanalytical Laboratory, Imaging Core Laboratory, Cardiovascular & ECG Core Laboratory, and a Phase I Unit. The full breadth of CRO services — regulatory affairs, clinical trial management, clinical monitoring, biostatistics, pharmacovigilance, medical writing, quality assurance, patient recruitment, and clinical packaging — is delivered through a therapeutically-focused, single-vendor model, with therapeutic depth across oncology, cardiovascular, rare diseases, cell and gene therapy, and other specialty areas.
Differentiator
Problem solved
Functional benefit
Brands
- ClinTrak: Proprietary clinical trial management system (CTMS) platform used for study management, data capture, and operational oversight.
- TrialPACE
- IntelliPACE
- ExcelliPACE
- Trusted by Biotech
Products and services
- Full-Service CRO
Quantifiable outcome
- Q1 2026 revenue of $706.6 million representing 26.5% year-over-year growth, indicating strong customer demand and execution
- +2 more outcomes
Companies that use Medpace
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Medpace technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Medpace partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Society for Clinical Research Sites (SCRS)coreMedpace maintains an active partnership with SCRS, a leading global organization representing clinical research sites. The relationship involves ongoing collaboration to support site sustainability, advance site-CRO relationships, and participate in industry advocacy initiatives. Medpace's recognition with the SCRS Eagle Award reflects the depth of this engagement.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Medpace competitors and assessment
Company assessmentBroad incumbents
- IQVIA Holdings: IQVIA is the largest global CRO and life sciences technology provider, offering full-service clinical development alongside real-world data and analytics. It competes directly with Medpace for biotech sponsor engagements but operates at a much broader scale across the entire life sciences value chain.
- Thermo Fisher Scientific (PPD): Thermo Fisher acquired PPD to build a leading global clinical development services franchise. As a large diversified life sciences platform, PPD competes with Medpace for biotech clinical trials while offering broader analytical instruments and pharma services breadth.
- Charles River Laboratories: Charles River provides preclinical and clinical CRO services plus manufacturing solutions to biotech and pharma. While its core is preclinical, its clinical services and biologics capabilities overlap with Medpace's drug development offerings for emerging sponsors.
- Labcorp (incl. Fortrea): Labcorp owns central lab services and spun out Fortrea as the clinical CRO business. Both arms overlap with Medpace's central lab and full-service CRO offerings, and Labcorp/Fortrea are frequent bidders against Medpace on biotech programs.
Direct peers
- ICON plc: ICON is a global full-service CRO formed via the PRA Health Sciences merger, serving biotech and pharma sponsors across all clinical phases. Head-to-head competitor to Medpace for biotech clinical trial outsourcing, particularly in oncology and rare disease.
- PSI CRO: PSI CRO is a privately-held full-service CRO with strong biotech sponsor coverage across oncology, rare disease, and other specialty areas. It competes directly with Medpace for full-service clinical trial outsourcing engagements from mid-sized biotechs.
- Parexel International: Parexel is a global full-service CRO with strong biotech and mid-market sponsor coverage, owned by EQT/Goldman Sachs Asset Management. It competes directly with Medpace for full-service clinical development work across therapeutic areas.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized full-service CRO focused on complex therapeutic areas including CNS, oncology, and rare diseases. It competes with Medpace for mid-sized biotech sponsor work and shares a similar scientific-focus positioning.
- Syneos Health: Syneos Health is a full-service biopharmaceutical solutions organization covering clinical and commercial services, with strong biotech sponsor relationships. Now privately held after Elliott/Veritas-led take-private, it competes directly with Medpace on clinical trial outsourcing.
Regional players
- WuXi AppTec: WuXi AppTec is a leading China-based CRO/CDMO offering preclinical, clinical, and bioanalytical services globally. It is a comparable full-service clinical CRO, though recent US BIOSECURE legislation has constrained its ability to serve US biotech sponsors — a dynamic relevant to Medpace's competitive positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Medpace social profiles
Digital presenceMedpace financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medpace leadership team
Management profileNumber of profiles
Profiles13 records
Medpace subsidiaries and ownership
Company hierarchySubsidiaries8 records
Medpace funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medpace M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medpace
What does Medpace do?
Medpace is a global full-service Contract Research Organization (CRO) that provides end-to-end clinical development services for pharmaceutical and biotechnology sponsors across preclinical through Phase IV. Its offerings are anchored by the proprietary ClinTrak technology platform and supported by wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, Cardiovascular & ECG Core Lab, and a Phase I Unit, delivering study start-up, clinical trial management, monitoring, regulatory affairs, biostatistics, pharmacovigilance, medical writing, and quality assurance through a single-vendor outsourcing model.
Is Medpace a public or private company?
Medpace is a public company. It is classified as public and is currently operating.
When was Medpace founded?
Medpace was founded in 1992. It employs 5,001 to 10,000 people.
Where is Medpace based?
Medpace is headquartered in Cincinnati, United States, in the North America region.
How does Medpace make money?
One revenue line is on record: contract Research Services.
Who are Medpace's main competitors?
Broad incumbents on record are IQVIA Holdings, Thermo Fisher Scientific (PPD), Charles River Laboratories and Labcorp (incl. Fortrea). Direct peers are ICON plc, PSI CRO, Parexel International, Worldwide Clinical Trials and Syneos Health. WuXi AppTec is listed as a regional player.
Does Medpace have an API?
No public API is recorded for Medpace.
What industry is Medpace in?
Medpace's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 54171 and its SIC code is 8731.